# OnCo record nct05862337 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05862337/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05862337", "NCT05862337" ;
  schema:name "Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence."@en ;
  schema:description "A phase 3 trial of Anlotinib, Penpulimab in hepatocellular carcinoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05862337/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05862337> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-05-10" ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-early/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/anlotinib/>, <https://onco.cc/drugs/penpulimab/> ;
  onco:companies <https://onco.cc/companies/sino-biopharm/> .